These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9361171)

  • 1. Lack of effect of omeprazole in oral acenocoumarol anticoagulant therapy.
    Vreeburg EM; De Vlaam-Schluter GM; Trienekens PH; Snel P; Tytgat GN
    Scand J Gastroenterol; 1997 Oct; 32(10):991-4. PubMed ID: 9361171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics.
    de Hoon JN; Thijssen HH; Beysens AJ; Van Bortel LM
    Br J Clin Pharmacol; 1997 Oct; 44(4):399-401. PubMed ID: 9354316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug interaction: omeprazole and phenprocoumon.
    Enderle C; Müller W; Grass U
    BMC Gastroenterol; 2001; 1():2. PubMed ID: 11313000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interaction of the prostaglandin E derivative rioprostil with oral anticoagulant agents.
    Thijssen HH; Hamulyàk K
    Clin Pharmacol Ther; 1989 Jul; 46(1):110-6. PubMed ID: 2501056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lansoprazole and omeprazole in the treatment of acid peptic disorders.
    Blum RA
    Am J Health Syst Pharm; 1996 Jun; 53(12):1401-15. PubMed ID: 8781686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prolonged diminished effect of coumarin derivatives after use of rifampicin].
    Harmsze AM; Deneer VH; Wiltink EH
    Ned Tijdschr Geneeskd; 2007 Sep; 151(35):1945-9. PubMed ID: 17907547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon.
    Becker ML; Franken WP; Karapinar F; Verzijl-Zeegers R; Schalekamp T; van der Hoeven RT
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1461-5. PubMed ID: 26400679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
    Sunkara G; Bigler H; Wang Y; Smith H; Prasad P; McLeod J; Ligueros-Saylan M
    Curr Med Res Opin; 2004 Jan; 20(1):41-8. PubMed ID: 14741071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic variations of acenocoumarol orally administrated either once or twice daily in patients with deep venous thrombosis.
    Mismetti P; Reynaud J; Laporte-Simitsidis S; Thijssen H; Tardy-Poncet B; Tardy B; Buchmuller A; Decousus H
    Fundam Clin Pharmacol; 1998; 12(6):631-5. PubMed ID: 9818296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer.
    Furuta T; Ohashi K; Kamata T; Takashima M; Kosuge K; Kawasaki T; Hanai H; Kubota T; Ishizaki T; Kaneko E
    Ann Intern Med; 1998 Dec; 129(12):1027-30. PubMed ID: 9867757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Miconazole oral gel enhances acenocoumarol anticoagulant activity: a report of three cases.
    Ortín M; Olalla JI; Muruzábal MJ; Peralta FG; Gutiérrez MA
    Ann Pharmacother; 1999 Feb; 33(2):175-7. PubMed ID: 10084413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
    Ufer M
    Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose vitamin K1 versus short-term with holding of acenocoumarol in the treatment of excessive anticoagulation episodes induced by acenocoumarol. A retrospective comparative study.
    Ortín M; Olalla J; Marco F; Velasco N
    Haemostasis; 1998; 28(2):57-61. PubMed ID: 10087429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No clinically relevant effect of lornoxicam intake on acenocoumarol pharmacokinetics and pharmacodynamics.
    Masche UP; Rentsch KM; von Felten A; Meier PJ; Fattinger KE
    Eur J Clin Pharmacol; 1999 Jan; 54(11):865-8. PubMed ID: 10027662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A placebo-controlled study of interaction between nabumetone and acenocoumarol.
    Pardo A; García-Losa M; Fernández-Pavón A; del Castillo S; Pascual-García T; García-Méndez E; Dal-Ré R
    Br J Clin Pharmacol; 1999 Apr; 47(4):441-4. PubMed ID: 10233210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of acenocoumarol on hemorheological parameters.
    Vayá A; Martínez M; Fernández A; Ripoll F; Moscardó F; Mira Y; Aznar J
    Clin Hemorheol Microcirc; 2001; 24(2):111-5. PubMed ID: 11381186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension.
    Pulido T; Sandoval J; Roquet I; Gutiérrez R; Rueda T; Peña H; Santos E; Miranda MT; Lupi E
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():14-8. PubMed ID: 19335742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with acenocoumarol treatment and migraine.
    Morales-Asín F; Iñiguez C; Cornudella R; Mauri JA; Espada F; Mostacero EE
    Headache; 2000 Jan; 40(1):45-7. PubMed ID: 10759903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe interaction between ritonavir and acenocoumarol.
    Llibre JM; Romeu J; López E; Sirera G
    Ann Pharmacother; 2002 Apr; 36(4):621-3. PubMed ID: 11918509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.